The 'Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug

BACKGROUND: Rheumatoid Arthritis (RA) is one of the most common autoimmune diseases, affecting approximately 1% of the UK adult population. Patients suffer considerable pain, stiffness and swelling and can sustain various degrees of joint destruction, deformity, and significant functional decline. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarro Coy, Nuria C, Brown, Sarah, Bosworth, Ailsa, Davies, Claire T, Emery, Paul, Everett, Colin C, Fernandez, Catherine, Gray, Janine C, Hartley, Suzanne, Hulme, Claire, Keenan, Anne-Maree, McCabe, Christopher, Redmond, Anthony, Reynolds, Catherine, Scott, David, Sharples, Linda D, Pavitt, Sue, Buch, Maya H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391115/
https://www.ncbi.nlm.nih.gov/pubmed/25539805
http://dx.doi.org/10.1186/1471-2474-15-452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391115/
https://www.ncbi.nlm.nih.gov/pubmed/25539805
http://dx.doi.org/10.1186/1471-2474-15-452

Ejemplares similares